Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Prelude Therapeutics Inc PRLD

Healthcare Biotechnology
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PRLD)

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

GlobeNewswire April 9, 2024

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

GlobeNewswire March 5, 2024

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

GlobeNewswire February 29, 2024

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

GlobeNewswire February 15, 2024

Prelude Therapeutics Announces $25 Million Private Placement

GlobeNewswire December 11, 2023

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

GlobeNewswire November 1, 2023

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

GlobeNewswire November 1, 2023

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference 

GlobeNewswire October 14, 2023

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

GlobeNewswire August 29, 2023
View More News ››

Opinion & Analysis (NDAQ:PRLD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PRLD)

Prelude Highlights Continued Strength of Discovery Engine at

News; $PRLD Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingHighly selective oral SMARCA2 degrader,...
whytestocks - April 9, 2024

5 BIOTECH STOCKS INSIDERS ARE BUYING!

$KRON $EYEN $PRLD $NBSE $KDNY Insider selling or buying cannot be the sole indicator for investing in a stock, but it would be wise...
AviseAnalytics - September 1, 2021
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia is a digital asset business that builds and targets investments in early and growth-stage technology companies that ...
View More »